Michael B. Jordan, MD

Emapalumab use in malignancy-associated hemophagocytic lymphohistiocytosis in the United States: The REAL-HLH study. Zoref-Lorenz, A; Allen, CE; Behrens, EM; Chandrakasan, S; Chien, M; Hermiston, ML; Hinson, A; Intzes, S; Isakoff, MS; Leiding, JW; Walkovich, K; Weinstein, JL; Yee, JD; Jordan, MB. Blood advances. 2025.

Novel CSF Biomarkers for facilitating diagnosis of CNS-HLH from other Neuroinflammatory Disorders. Chandra, S; Greis, KD; Chutipongtanate, S; Luebbering, N; Webster, A; Poisson, K; Fisher, K; Smiley, K; Marsh, RA; Jordan, MB; Davies, SM. Blood advances. 2025.

Use of emapalumab is associated with rapid and sustained benefits in primary HLH subgroups, including CNS involvement and previously untreated patients: Pooled analysis of prospective trials NI-0501-04, NI-0501-05 and NI-0501-09. Locatelli, F; Jordan, M; Halimi, D; Burillo, E; Jamieson, B; Monnet, E; Danquah, A. Blood. 2025; 146(Supplement 1):2979-2979.

Mavs mediates inflammatory memory in hematopoietic stem cells and promotes ineffective hematopoiesis. Nasr, W; Pham, V; Xu, J; Jordan, M; Verma, A; Huang, G; Filippi, M-D. Blood. 2025; 146(Supplement 1):974.

Emapalumab induces rapid, durable responses and reliable bridging to curative HSCT in patients with primary HLH: Pooled analysis of prospective trials NI-0501-04, NI-0501-05 and NI-0501-09. Jordan, M; Locatelli, F; Halimi, D; Burillo, E; Jamieson, B; Danquah, A; Monnet, E. Blood. 2025; 146(Supplement 1):4758-4758.

The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma. Zoref-Lorenz, A; Murakami, J; Gurion, R; Iyer, SP; Abadi, U; Cohen, I; Goyal, G; Mohamed, S; Nikiforow, S; Natour, AEH; Itchaki, G; Izraeli, S; Ellis, M; Jordan, MB. Blood advances. 2025; 9(17):4515-4525.

Lipopolysaccharide-responsive and beige-like anchor protein (LRBA) functional deficiency caused by biallelic LRBA missense variants characterized by Evans syndrome or colitis. Chiang, SCC; Yang, L; Owsley, E; Husami, A; Akeno, N; Cobb, C; Hartog, NL; Elizalde, A; Seroogy, CM; Blanchard-Rohner, G; Marsh, R; Bleesing, J; Jordan, MB; Marwaha, AK. Journal of Allergy and Clinical Immunology. 2025; 156(2):270-278.

Recognizing and Managing Secondary Hemophagocytic Lymphohistiocytosis in Adults: A Practical Clinical Guide. Zoref-Lorenz, A; Rocco, J; Schwartz, DM; Jordan, M. Hematology/Oncology Clinics of North America. 2025; 39(3):577-596.

The optimized HLH inflammatory index: A novel prognostic tool for newly diagnosed patients with diffuse large B-cell lymphoma—Discovery and validation. Zoref Lorenz, A; Cahn, E; Mou, E; Wang, Y; Maurer, MJ; Feldman, AL; Negaard, BJ; Mwangi, R; Itchaki, G; Nowakowski, GS; Goyal, G; Witzig, TE; Cerhan, JR; Jordan, M. Journal of Clinical Oncology. 2025; 43(16_suppl):7073-7073.

122 | IDENTIFYING HARMFUL HYPERINFLAMMATION IN DIFFUSE LARGE B‐CELL LYMPHOMA USING THE OHI (OPTIMIZED HLH INFLAMMATORY) INDEX—DISCOVERY AND VALIDATION IN REAL‐WORLD PATIENTS. Zoref‐Lorenz, A; Cahn, EJ; Mou, E; Cholack, G; Wang, Y; Maurer, M; Feldman, AL; Negaard, BJ; Mwangi, R; Itchaki, G; Novak, AJ; Witzig, TE; Cerhan, JR; Jordan, M. Hematological Oncology. 2025; 43(S3).